With deceptively similar drug names, these medicines heighten the chances of medication errors, endangering patient safety, particularly in low- and middle-income regions.
Published Oct 30, 2024 | 3:08 PM ⚊ Updated Oct 30, 2024 | 3:08 PM
Dr Parth Sharma, a community physician and public health researcher, delves into the serious risks associated with Look-Alike, Sound-Alike (LASA) medicines in India.
With deceptively similar drug names, these medicines heighten the chances of medication errors, endangering patient safety, particularly in low- and middle-income regions.
Drawing from his article in The Lancet, Dr Sharma explains strategies to reduce these risks and create safer practices within the pharmaceutical industry. Discover how healthcare providers, patients, and policymakers can join forces to avoid these critical errors

Oct 18, 2025

Oct 14, 2025

Oct 05, 2025

Oct 05, 2025

Sep 26, 2025

Sep 15, 2025